Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation

Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and systemic thromboembolism (embolism in the vessels of the systemic circulation, systemic embolism) in terms of pharmacoeconomic indicators. Materials and Methods. The economic assessment was carried out from the standpoint of the healthcare system of the Russian Federation. We used published data on the clinical efficacy and safety of DOACs, which were obtained earlier in clinical trials. The efficacy of therapy was assessed by the incidence of ischemic stroke (IS) of systemic embolism (SE), while the safety was assessed by the incidence of major bleeding (MB) and clinically signifi cant minor bleeding (CSNMB). The total cost of patient management for each alternative treatment option included both the cost of drug therapy and the cost of managing adverse events over a study horizon of 12 months. The conclusion about the most preferred alternative was made on the basis of the ratio of effectiveness and cost of treating the patient. Results. The use of apixaban to prevent IS or SE in patients with AF was accompanied by a decrease in the incidence of their development (HR 0.80, 95 % CI 0.73–0.89; HR 0.72, 95 % CI 0.60–0.85 — compared with rivaroxaban and dabigatran, respectively), as well as a decrease in the frequency of MB compared with other DOACs (HR 0.55, 95 % CI 0.53–0.59; HR 0.78, 95 % CI 0.70–0.87 — compared with rivaroxaban and dabigatran, respectively). Since apixaban was more effective and safer than rivaroxaban and dabigatran, a cost-effectiveness approach was applied in this study. The least expensive treatment regimen included apixaban, the direct cost was 33,263 roubles per patient. The advantage was achieved both due to the lower of therapy with apixaban (29.6–34.0 % lower than other DOACs) and the minimum cost of managing the adverse events: for MB and CSNMB, it was reduced by 20.7 % compared to dabigatran and by 44.7 % compared to rivaroxaban; for stroke/SE, it was reduced by 25.9 % and 20.6 %, respectively. Conclusion. In patients with AF, apixaban was more cost-effective compared with rivaroxaban or dabigatran for preventing IS and SE, as it led to higher clinical efficacy and safety while requiring less healthcare system costs.

1. Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM. Atrial fibrillation: stroke prevention in focus. Aust Crit Care. 2014 May;27(2):92–8. doi:10.1016/j.aucc.2013.08.002

2. Deitelzweig SB, Pinsky B, Buysman E, Lacey M, Makenbaeva D, Wiederkehr D, Graham J. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther. 2013 Oct;35(10):1536–45.e1. doi:10.1016/j.clinthera.2013.08.013

3. Fitch K, Broulette J, Kwong WJ. The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: A retrospective claims analysis. Am Health Drug Benefits. 2014 Jun;7(4):200–9.

4. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001 Nov;86(5):516–21. doi:10.1136/heart.86.5.516

5. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001 May 9;285(18):2370–5. doi:10.1001/jama.285.18.2370

6. Heeringa J, Van Der Kuip DAM, Hofman A, Kors JA, Van Herpen G, Stricker BHC, Stijnen T, Lip GYH, Witteman JCM. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2 2006 Apr;27(8):949–53. doi:10.1093/eurheartj/ehi825

7. Sterne JAC, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, Thom HHZ, Caldwell DM, Dias S, Eaton D, Higgins JPT, Hollingworth W, Salisbury C, Savović J, Sofat R, Stephens-Boal A, Welton NJ, Hingorani AD. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017 Mar;21(9):1–386. doi:10.3310/hta21090

8. Machinskiy PA, Plotnikova NA, Ul’yankin VE, Rybakov AG, Makeev DA. Comparative characteristics of the ischemic and hemorrhagic stroke morbidity indicators in Russia. University proceedings. Volga region. Medical sciences. Morbid anatomy. 2019;2(50):112–32. (In Russ). doi:10.21685/2072-3032-2019-2-11

9. Fibrillyaciya i trepetanie predserdij u vzroslyh. Klinicheskie rekomendacii Obshcherossijskoj obshchestvennoj organizacii “Rossijskoe kardiologicheskoe obshchestvo”, Vserossijskogo nauchnogo obshchestva specialistov po klinicheskoj elektrofiziologii, aritmologii i elektrostimulyacii i Associacii serdechno- sosudistyh hirurgov Rossii, (n. d.). (In Russ). https://cr.minzdrav.gov.ru/recomend/382_1 (accessed October 29, 2021)

10. Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. 2016 Nov 1;176(11):1662–71. doi:10.1001/jamainternmed.2016.5954

11. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014 May;62(5):857–64. doi:10.1111/jgs.12799

12. Lip GY, Lane DA. Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation — focus on the elderly. Circ J. 2013;77(6):1380–8. doi:10.1253/circj.cj-13-0465

13. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov;33(22):2821–30. doi:10.1093/eurheartj/ehs274

14. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S, O’Donnell M, Yusuf S, Hart RG. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012 Aug;21(6):429–35. doi:10.1016/j.jstrokecerebrovasdis.2012.05.007

15. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012 Mar;107(3):584–9. doi:10.1160/TH11-11-0784

16. Lip GYH, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, Klem C, Ferri M, Jiang J, Yuce H, Deitelzweig S. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. JAMA Netw Open. 2021 Aug 2;4(8):e2120064. doi:10.1001/jamanetworkopen.2021.20064

17. Van Ganse E, Danchin N, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cotté FE, Gollety S, Falissard B, Belhassen M, Steg PG. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Stroke. 2020 Jul;51(7):2066–75. doi:10.1161/STROKEAHA.120.028825

18. López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savović J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017 Nov 28;359: j5058. doi:10.1136/bmj.j5058

19. Thom HHZ, Hollingworth W, Sofat R, Wang Z, Fang W, Bodalia PN, Bryden PA, Davies PA, Caldwell DM, Dias S, Eaton D, Higgins JPT, Hingorani AD, López-López JA, Okoli GN, Richards A, Salisbury C, Savović J, Stephens-Boal A, Sterne JAC, Welton NJ. Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis. MDM Policy Pract. 2019 Aug 17;4(2):2381468319866828. doi:10.1177/2381468319866828

20. Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2017 Feb;150:123–30. doi:10.1016/j.thromres.2016.10.006

21. Omelyanovsky VV, Avksentieva MV, Sura MV, Khachatryan GR, Gerasimova KV, Ivakhnenko OI, Dzanaeva AV. Metodicheskie rekomendacii po provedeniyu sravnitel’noj kliniko-ekonomicheskoj ocenki lekarstvennogo preparata (novaya redakciya). — Moscow: Nauka, 2018. (In Russ).

22. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018 Dec;49(12):2933–44. doi:10.1161/STROKEAHA.118.020232

23. Zhao YJ, Lin L, Zhou HJ, Tan KT, Chew AP, Foo CG, Oh CT, Lim BP, Lim WS. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. Int J Cardiol. 2016 Oct 1;220:794–801. doi:10.1016/j.ijcard.2016.06.087

24. Dilokthornsakul P, Nathisuwan S, Krittayaphong R, Chutinet A, Permsuwan U. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation. Heart Lung Circ. 2020 Mar;29(3):390–400. doi:10.1016/j.hlc.2019.02.187

25. Liao CT, Lee MC, Chen ZC, Ku LE, Wang JD, Toh HS. Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan. Acta Cardiol Sin. 2020 Jan;36(1):50–61. doi:10.6515/ACS.202001_36(1).20190511A

26. Lorenzoni V, Pirri S, Turchetti G. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective. Clin Drug Investig. 2021 Mar;41(3):255–67. doi:10.1007/s40261-021-01002-z

27. Hallinen T, Soini E, Asseburg C, Linna M, Eloranta P, Sintonen S, Kosunen M. Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation. Clinicoecon Outcomes Res. 2021 Aug 13;13:745–55. doi:10.2147/CEOR.S317078

28. Rudakova AV, Parfe nov VA. Cost-effectiveness of Apixaban as Compared with Warfarin and Acetylsalicylic Acid in Patients with Non-valvular Atrial Fibrillation in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2014;10(3):275–82. (In Russ). doi:10.20996/1819-6446-2014-10-3-275-282

29. Nedogoda SV, Barykina IN, Salasiuk AS, Smirnova VO. Clinical and Economical Comparison of Rivaroxaban and Apixaban Use in Patients with Non-Valvular Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2017;13(1):45–50. (In Russ). doi:10.20996/1819-6446-2017-13-1-45-50

30. Malchikova SV, Korobeinikova AN, Maksimchuk-Kolobova NS, Kazakovtseva MV. Prognosis of the influence of direct oral anticoagulants on the direct medical expenses in patients with atrial fibrillation. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(2):124–31. (In Russ). doi:10.17749/2070-4909/farmakoekonomika.2020.025

31. Lip GYH, Keshishian AV, Kang AL, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Garcia Reeves AB, Yuce H, Deitelzweig S. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2021 Jan;289(1):42–52. doi:10.1111/joim.13140

32. Correction to: Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients: The ARISTOPHANES Study. Stroke. 2020 Apr;51(4): e71. doi:10.1161/STR.0000000000000227